Novartis' Gilenya patent survives invalidity bid

Novartis has convinced a Delaware court that a patent for its flagship multiple sclerosis treatment Gilenya (fingolimod) is directed at patent-eligible matter, dismissing a challenge from Handa Pharmaceuticals that the patent is directed at natural phenomena and invalid.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Roche asks court for halt of Novartis unit’s generic launch

4 April 2022 Roche’s subsidiary Genentech has asked a Delaware court to block two of Novartis’ units from selling a generic version of the blockbuster lung-disease drug Esbriet.

Americas

Novartis, Dana-Farber seek to bar generic leukaemia drug

9 June 2022 Novartis Pharmaceuticals and the Dana-Farber Cancer Institute have filed two lawsuits to bar generic versions of leukaemia drug, Rydapt.

Generics

Novartis sued over blockbuster heart failure drug

30 August 2022 Pharma company facing lawsuit from two universities | Dispute centres on therapeutically effective co-crystals patent.

More on this story

Big Pharma

Roche asks court for halt of Novartis unit’s generic launch

4 April 2022 Roche’s subsidiary Genentech has asked a Delaware court to block two of Novartis’ units from selling a generic version of the blockbuster lung-disease drug Esbriet.

Americas

Novartis, Dana-Farber seek to bar generic leukaemia drug

9 June 2022 Novartis Pharmaceuticals and the Dana-Farber Cancer Institute have filed two lawsuits to bar generic versions of leukaemia drug, Rydapt.

Generics

Novartis sued over blockbuster heart failure drug

30 August 2022 Pharma company facing lawsuit from two universities | Dispute centres on therapeutically effective co-crystals patent.

More on this story

Big Pharma

Roche asks court for halt of Novartis unit’s generic launch

4 April 2022 Roche’s subsidiary Genentech has asked a Delaware court to block two of Novartis’ units from selling a generic version of the blockbuster lung-disease drug Esbriet.

Americas

Novartis, Dana-Farber seek to bar generic leukaemia drug

9 June 2022 Novartis Pharmaceuticals and the Dana-Farber Cancer Institute have filed two lawsuits to bar generic versions of leukaemia drug, Rydapt.

Generics

Novartis sued over blockbuster heart failure drug

30 August 2022 Pharma company facing lawsuit from two universities | Dispute centres on therapeutically effective co-crystals patent.